

**TAZORAC- tazarotene cream**  
**Allergan, Inc.**

-----  
**HIGHLIGHTS OF PRESCRIBING INFORMATION**

These highlights do not include all the information needed to use TAZORAC® Cream safely and effectively.

See full prescribing information for TAZORAC® Cream.

TAZORAC® (tazarotene) cream, 0.05% and 0.1%, for topical use

Initial U.S. Approval: 1997

-----  
**INDICATIONS AND USAGE**

- TAZORAC® Cream 0.05% and 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. (1.1)
- TAZORAC Cream 0.1% is indicated for the topical treatment of acne vulgaris. (1.2)

-----  
**DOSAGE AND ADMINISTRATION**

- Apply a thin layer of TAZORAC Cream only to the affected area once daily in the evening. (2.1, 2.2)
- Not for ophthalmic, oral, or intravaginal use. (2.2)
- If contact with eyes occurs, rinse thoroughly with water. (2.2)

-----  
**DOSAGE FORMS AND STRENGTHS**

Cream, 0.05% and 0.1%. (3)

-----  
**CONTRAINDICATIONS**

- Pregnancy (4, 8.1)
- Hypersensitivity (4)

-----  
**WARNINGS AND PRECAUTIONS**

- Embryofetal Toxicity: TAZORAC Cream contains tazarotene, which is a teratogenic substance. TAZORAC Cream is contraindicated in pregnancy. Females of child-bearing potential should have a negative pregnancy test within 2 weeks prior to initiating treatment and use an effective method of contraception during treatment. (5.1)
- Local Irritation: Some individuals may experience excessive pruritus, burning, skin redness or peeling. If these effects occur, discontinue until the integrity of the skin has been restored, or reduce dosing interval, or in the case of psoriasis, may switch to the lower concentration. TAZORAC Cream should not be used on eczematous skin, as it may cause severe irritation. (5.2)
- Photosensitivity and Risk for Sunburn: Avoid exposure to sunlight, sunlamps, and weather extremes. Wear sunscreen daily. TAZORAC Cream should be administered with caution if the patient is also taking drugs known to be photosensitizers. (5.3)

-----  
**ADVERSE REACTIONS**

- Plaque psoriasis: Most common adverse reactions occurring in 10 to 23% of patients are pruritus, erythema, and burning. (6.1)
- Acne Vulgaris: Most common adverse reactions occurring in 10 to 30% of patients are desquamation, dry skin, erythema, and burning sensation. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-678-1605 or FDA at 1-800-FDA-1088 or [www.fda.gov/medwatch](http://www.fda.gov/medwatch).

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 7/2017

---

**FULL PRESCRIBING INFORMATION: CONTENTS\***

**1 INDICATIONS AND USAGE**

1.1 Plaque Psoriasis

1.2 Acne Vulgaris

**2 DOSAGE AND ADMINISTRATION**

2.1 Important Administration Instructions

2.2 Psoriasis

2.3 Acne

**3 DOSAGE FORMS AND STRENGTHS**

**4 CONTRAINDICATIONS**

**5 WARNINGS AND PRECAUTIONS**

5.1 Embryofetal Toxicity

5.2 Local Irritation and Hypersensitivity Reactions

5.3 Photosensitivity and Risk for Sunburn

**6 ADVERSE REACTIONS**

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

**7 DRUG INTERACTIONS**

**8 USE IN SPECIFIC POPULATIONS**

8.1 Pregnancy

8.2 Lactation

8.3 Females and Males of Reproductive Potential

8.4 Pediatric Use

8.5 Geriatric Use

**10 OVERDOSAGE****11 DESCRIPTION****12 CLINICAL PHARMACOLOGY**

12.1 Mechanism of Action

12.3 Pharmacokinetics

**13 NONCLINICAL TOXICOLOGY**

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

**14 CLINICAL STUDIES****16 HOW SUPPLIED/STORAGE AND HANDLING****17 PATIENT COUNSELING INFORMATION**

\* Sections or subsections omitted from the full prescribing information are not listed.

---

**FULL PRESCRIBING INFORMATION****1 INDICATIONS AND USAGE****1.1 Plaque Psoriasis**

TAZORAC<sup>®</sup> (tazarotene) Cream, 0.05% and 0.1% are indicated for the topical treatment of patients with plaque psoriasis.

**1.2 Acne Vulgaris**

TAZORAC (tazarotene) Cream, 0.1% is also indicated for the topical treatment of patients with acne vulgaris.

**2 DOSAGE AND ADMINISTRATION****2.1 Important Administration Instructions**

TAZORAC Cream is for topical use only. TAZORAC Cream is not for ophthalmic, oral, or intravaginal use. If contact with mucous membranes occurs, rinse thoroughly with water [see Warnings and Precaution (5.2)].

Wash hands thoroughly after application.

**2.2 Psoriasis**

It is recommended that treatment starts with TAZORAC Cream, 0.05%, with strength increased to 0.1% if tolerated and medically indicated. Apply a thin film (2 mg/cm<sup>2</sup>) of TAZORAC Cream once per day, in the evening, to cover only the psoriatic lesions. If a bath or shower is taken prior to application, the skin should be dry before applying the cream. If emollients are used, they should be applied at least an hour before application of TAZORAC Cream. Because unaffected skin may be more susceptible to irritation, application of TAZORAC Cream to these areas should be carefully avoided.

**2.3 Acne**

Cleanse the face gently. After the skin is dry, apply a thin layer (2 mg/cm<sup>2</sup>) of TAZORAC Cream 0.1% once per day, in the evening, to the skin areas where acne lesions appear. Use enough to cover the entire affected area.

Use effective sunscreens and wear protective clothing while using TAZORAC Cream [see Warnings and Precaution (5.3)].

**3 DOSAGE FORMS AND STRENGTHS**

Cream, 0.05% and 0.1%. Each gram of TAZORAC Cream, 0.05% and 0.1% contains 0.5 mg and 1 mg of tazarotene, respectively in a white cream base.

**4 CONTRAINDICATIONS**

TAZORAC Cream is contraindicated in :

- Pregnancy. Retinoids may cause fetal harm when administered to a pregnant female [see Warnings and Precautions (5.1), Use in Specific Populations (8.1, 8.3)].
- Individuals who have known hypersensitivity to any of its components [see Warnings and Precautions (5.2)].

**5 WARNINGS AND PRECAUTIONS****5.1 Embryofetal Toxicity**

Systemic exposure to tazarotenic acid is dependent upon the extent of the body surface area treated. In patients treated topically over sufficient body surface area, exposure could be in the same order of magnitude as in orally treated animals. Although there may be less systemic exposure in the treatment of acne of the face alone due to less surface area for application, tazarotene is a teratogenic substance, and it is not known what level of exposure is required for teratogenicity in humans [see *Clinical Pharmacology (12.3)*].

There were thirteen reported pregnancies in subjects who participated in the clinical trials for topical tazarotene. Nine of the subjects were found to have been treated with topical tazarotene, and the other four had been treated with vehicle. One of the subjects who was treated with tazarotene cream elected to terminate the pregnancy for non-medical reasons unrelated to treatment. The other eight pregnant women who were inadvertently exposed to topical tazarotene during clinical trials subsequently delivered apparently healthy babies. As the exact timing and extent of exposure in relation to the gestation times are not certain, the significance of these findings is unknown.

#### *Females of Child-bearing Potential*

Females of child-bearing potential should be warned of the potential risk and use adequate birth-control measures when TAZORAC Cream is used. The possibility that a female of child-bearing potential is pregnant at the time of institution of therapy should be considered.

A negative result for pregnancy test should be obtained within 2 weeks prior to TAZORAC Cream therapy. TAZORAC Cream therapy should begin during a menstrual period [see *Use in Specific Populations (8.1)*].

### **5.2 Local Irritation and Hypersensitivity Reactions**

Local tolerability reactions (including blistering and skin desquamation) and hypersensitivity adverse reactions (including urticaria) have been observed with topical tazarotene. Application of TAZORAC Cream may cause excessive irritation in the skin of certain sensitive individuals. Some individuals may experience excessive pruritus, burning, skin redness or peeling. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the dosing should be reduced to an interval the patient can tolerate. However, efficacy at reduced frequency of application has not been established. Alternatively, patients with psoriasis who are being treated with the 0.1% concentration can be switched to the lower concentration. Frequency of application should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. Therapy can be resumed, or the drug concentration or frequency of application can be increased as the patient becomes able to tolerate treatment.

Concomitant topical medications and cosmetics that have a strong drying effect should be avoided. It is also advisable to "rest" a patient's skin until the effects of such preparations subside before use of TAZORAC Cream is begun.

TAZORAC Cream, should not be used on eczematous skin, as it may cause severe irritation.

Weather extremes, such as wind or cold, may be more irritating to patients using TAZORAC Cream.

### **5.3 Photosensitivity and Risk for Sunburn**

Because of heightened burning susceptibility, exposure to sunlight (including sunlamps) should be avoided unless deemed medically necessary, and in such cases, exposure should be minimized during the use of TAZORAC Cream. Patients must be warned to use sunscreens and protective clothing when using TAZORAC Cream. Patients with sunburn should be advised not to use TAZORAC Cream until fully recovered. Patients who may have considerable sun exposure due to their occupation and those patients with inherent sensitivity to sunlight should exercise particular caution when using TAZORAC Cream.

TAZORAC Cream should be administered with caution if the patient is also taking drugs known to be photosensitizers (e.g., thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides) because of the increased possibility of augmented photosensitivity.

## **6 ADVERSE REACTIONS**

The following serious adverse reactions are discussed in more detail in other sections of the labeling:

- Embryofetal toxicity [see *Warnings and Precautions (5.1)*]
- Photosensitivity and Risk of Sunburn [see *Warnings and Precautions (5.3)*]

### **6.1 Clinical Trials Experience**

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In human dermal safety trials, TAZORAC Cream, 0.05% and 0.1% did not induce allergic contact sensitization, phototoxicity, or photoallergy.

### **Psoriasis**

The most frequent adverse reactions reported with TAZORAC Cream, 0.05% and 0.1% occurring in 10 to 23% of subjects, in descending order, included pruritus, erythema, and burning. Reactions occurring in greater than 1 to less than 10% of subjects, in descending order, included irritation, desquamation, stinging, contact dermatitis, dermatitis, eczema, worsening of psoriasis, skin pain, rash, hypertriglyceridemia, dry skin, skin inflammation, and peripheral edema.

TAZORAC Cream, 0.1% was associated with a greater degree of local irritation than the 0.05% cream. The rates of irritation adverse reactions reported during psoriasis trials with TAZORAC Cream, 0.1% were 0.1-0.4% higher than those reported for TAZORAC Cream, 0.05%.

## Acne

The most frequent adverse reactions reported during clinical trials with TAZORAC Cream 0.1% in the treatment of acne, occurring in 10-30% of subjects, in descending order included desquamation, dry skin, erythema, and burning sensation. Reactions occurring in 1 to 5% of subjects included pruritus, irritation, face pain, and stinging.

## 6.2 Postmarketing Experience

The following adverse reactions have been identified during postapproval use of tazarotene. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

**Skin and subcutaneous tissue disorders:** blister, dermatitis, urticaria, skin exfoliation, skin discoloration (including skin hyperpigmentation or skin hypopigmentation), swelling at or near application sites, and pain.

## 7 DRUG INTERACTIONS

No formal drug-drug interaction studies were conducted with TAZORAC Cream.

In a trial of 27 healthy female subjects between the ages of 20–55 years receiving a combination oral contraceptive tablet containing 1 mg norethindrone and 35 mcg ethinyl estradiol, concomitant use of tazarotene administered as 1.1 mg orally (mean  $\pm$  SD  $C_{max}$  and  $AUC_{0-24}$  of tazarotenic acid were  $28.9 \pm 9.4$  ng/mL and  $120.6 \pm 28.5$  ng\*hr/mL) did not affect the pharmacokinetics of norethindrone and ethinyl estradiol over a complete cycle.

The impact of tazarotene on the pharmacokinetics of progestin only oral contraceptives (i.e., minipills) has not been evaluated.

## 8 USE IN SPECIFIC POPULATIONS

### 8.1 Pregnancy

#### Risk Summary

Based on data from animal reproduction studies, retinoid pharmacology, and the potential for systemic absorption, TAZORAC Cream may cause fetal harm when administered to a pregnant female and is contraindicated during pregnancy. Safety in pregnant females has not been established. The potential risk to the fetus outweighs the potential benefit to the mother from TAZORAC Cream during pregnancy; therefore, TAZORAC Cream should be discontinued as soon as pregnancy is recognized [see *Contraindications (4), Warnings and Precautions (5.1), Clinical Pharmacology (12.3)*]. Limited case reports of pregnancy in females enrolled in clinical trials for TAZORAC Cream have not established a clear association with tazarotene and major birth defects or miscarriage risk. Because the exact timing and extent of exposure in relation to the gestational age are not certain, the significance of these findings is unknown.

In animal reproduction studies with pregnant rats, tazarotene dosed topically during organogenesis at 2 times the maximum systemic exposure in subjects treated with the maximum recommended human dose (MRHD) of tazarotene cream, 0.1% resulted in reduced fetal body weights and reduced skeletal ossification. In animal reproduction studies with pregnant rabbits dosed topically with tazarotene gel at 26 times the maximum systemic exposure in subjects treated with the MRHD of tazarotene cream, 0.1%, there was a single incident of known retinoid malformations, including spina bifida, hydrocephaly, and heart anomalies.

In animal reproduction studies with pregnant rats and rabbits, tazarotene dosed orally during organogenesis at 2 and 52 times, respectively, the maximum systemic exposure in subjects treated with the MRHD of tazarotene cream, 0.1% resulted in malformations, fetal toxicity, developmental delays, and/or behavioral delays. In pregnant rats, tazarotene dosed orally prior to mating through early gestation resulted in decreased litter size, decreased numbers of live fetuses, decreased fetal body weights, and increased malformations at doses approximately 7 times higher than the maximum systemic exposure in subjects treated with the MRHD of tazarotene cream, 0.1% [see *Data*].

The background risk of major birth defects and miscarriage for the indicated population is unknown. Adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.

## Data

### *Animal Data*

In rats, a tazarotene gel, 0.05% formulation dosed topically during gestation days 6 through 17 at 0.25 mg/kg/day, which represented 2 times the maximum systemic exposure in subjects treated with the MRHD of tazarotene cream, 0.1% (*i.e.*, 2 mg/cm<sup>2</sup> over a 15% body surface area), resulted in reduced fetal body weights and reduced skeletal ossification. Rabbits dosed topically with 0.25 mg/kg/day tazarotene gel, which represented 26 times the maximum systemic exposure in subjects treated with MRHD of tazarotene cream, 0.1%, during gestation days 6 through 18, had a single incident of known retinoid malformations, including spina bifida, hydrocephaly, and heart anomalies.

When tazarotene was given orally to animals, developmental delays were seen in rats, and malformations and post-implantation loss were observed in rats and rabbits at doses representing 2 and 52 times, respectively, the maximum systemic exposure seen in subjects treated with the MRHD of tazarotene cream, 0.1%.

In female rats orally administered 2 mg/kg/day of tazarotene from 15 days before mating through gestation day 7, which represented 7 times the maximum systemic exposure in subjects treated with the MRHD of tazarotene cream, 0.1%, classic developmental effects of retinoids were observed including decreased number of implantation sites, decreased litter size, decreased numbers of live fetuses, and decreased fetal body weights. A low incidence of retinoid-related malformations was observed at that dose.

In a pre- and postnatal development toxicity study, topical administration of tazarotene gel (0.125 mg/kg/day) to pregnant female rats from gestation day 16 through lactation day 20 reduced pup survival, but did not affect the reproductive capacity of the offspring. Based on data from another study, the maximum systemic exposure in the rat would be equivalent to the maximum systemic exposure in subjects treated with the MRHD of tazarotene cream, 0.1%.

## **8.2 Lactation**

### Risk Summary

There is no information regarding the presence of tazarotene in human milk, the effects on the breastfed infant, or the effects on milk production. After single topical doses of <sup>14</sup>C-tazarotene gel to the skin of lactating rats, radioactivity was detected in rat milk. The lack of clinical data during lactation precludes a clear determination of the risk of TAZORAC Cream to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TAZORAC Cream and any potential adverse effects on the breastfed child from TAZORAC Cream or from the underlying maternal condition.

## **8.3 Females and Males of Reproductive Potential**

### Pregnancy Testing

Pregnancy testing is recommended for females of reproductive potential within 2 weeks prior to initiating TAZORAC Cream therapy which should begin during a menstrual period.

### Contraception

#### *Females*

Based on animal studies, TAZORAC Cream may cause fetal harm when administered to a pregnant woman [see *Use in Specific Populations (8.1)*]. Advise females of reproductive potential to use effective contraception during treatment with TAZORAC Cream.

## **8.4 Pediatric Use**

The safety and efficacy of TAZORAC Cream have not been established in patients with psoriasis under the age of 18 years, or in patients with acne under the age of 12 years.

## **8.5 Geriatric Use**

TAZORAC Cream for the treatment of acne has not been clinically tested in persons 65 years of age or older.

Of the total number of subjects in clinical trials of TAZORAC Cream for plaque psoriasis, 120 were over the age of 65. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Currently there is no other clinical experience on the differences in responses between the elderly and younger subjects, but greater sensitivity of some older individuals cannot be ruled out.

## **10 OVERDOSAGE**


Excessive topical use of TAZORAC Cream, 0.05% and 0.1% may lead to marked redness, peeling, or discomfort [see *Warnings and Precautions (5.2)*].

TAZORAC Cream, 0.05% and 0.1% are not for oral use. Oral ingestion of the drug may lead to the same adverse effects as those associated with excessive oral intake of Vitamin A (hypervitaminosis A) or other retinoids. If oral ingestion occurs, the patient should be monitored, and appropriate supportive measures should be administered as necessary.

## 11 DESCRIPTION

TAZORAC (tazarotene) Cream, 0.05% and 0.1% is for topical use and contains the active ingredient, tazarotene. Each gram of TAZORAC Cream, 0.05% and 0.1% contains 0.5 and 1 mg of tazarotene, respectively in a white cream base.

Tazarotene is a member of the acetylenic class of retinoids. Chemically, tazarotene is ethyl 6-[(4,4-dimethylthiochroman-6-yl)ethynyl]nicotinate. The compound has an empirical formula of  $C_{21}H_{21}NO_2S$  and molecular weight of 351.46. The structural formula is shown below:



TAZORAC Cream contains the following inactive ingredients: benzyl alcohol 1%; carbomer 1342; carbomer homopolymer type B; edetate disodium; medium chain triglycerides; mineral oil; purified water; sodium hydroxide; sodium thiosulfate; and sorbitan monooleate.

## 12 CLINICAL PHARMACOLOGY

### 12.1 Mechanism of Action

Tazarotene is a retinoid prodrug which is converted to its active form, the carboxylic acid of tazarotene, by deesterification. Tazarotenic acid binds to all three members of the retinoic acid receptor (RAR) family: RAR $\alpha$ , RAR $\beta$ , and RAR $\gamma$ , but shows relative selectivity for RAR $\beta$ , and RAR $\gamma$  and may modify gene expression. The clinical significance of these findings is unknown.

### 12.3 Pharmacokinetics

Following topical application, tazarotene undergoes esterase hydrolysis to form its active metabolite, tazarotenic acid. Little parent compound could be detected in the plasma. Tazarotenic acid was highly bound to plasma proteins (greater than 99%). Tazarotene and tazarotenic acid were metabolized to sulfoxides, sulfones and other polar metabolites which were eliminated through urinary and fecal pathways. The half-life of tazarotenic acid was approximately 18 hours, following topical application of tazarotene to normal, acne or psoriatic skin.

In a multiple dose trial with a once daily dose for 14 consecutive days in 9 psoriatic subjects (male=5; female=4), measured doses of TAZORAC Cream, 0.1% were applied by medical staff to involved skin without occlusion (5 to 35% of total body surface area: mean  $\pm$  SD: 14  $\pm$  11%). The  $C_{max}$  of tazarotenic acid was 2.31  $\pm$  2.78 ng/mL occurring 8 hours after the final dose, and the  $AUC_{0-24h}$  was 31.2  $\pm$  35.2 ng·hr/mL on day 15 in the five subjects who were administered clinical doses of 2 mg cream/cm<sup>2</sup>.

During clinical trials with TAZORAC Cream, 0.05% or 0.1% treatment for plaque psoriasis, three out of 139 subjects with their systemic exposure monitored had detectable plasma tazarotene concentrations, with the highest value at 0.09 ng/mL. Tazarotenic acid was detected in 78 out of 139 subjects (LLOQ = 0.05 ng/mL). Three subjects using tazarotene cream 0.1% had plasma tazarotenic acid concentrations greater than 1 ng/mL. The highest value was 2.4 ng/mL. However, because of the variations in the time of blood sampling, the area of psoriasis involvement, and the dose of tazarotene applied, actual maximal plasma levels are unknown.

TAZORAC Cream 0.1% was applied once daily to either the face (N=8) or to 15% of body surface area (N=10) of female subjects with moderate to severe acne vulgaris. The mean  $C_{max}$  and AUC values of tazarotenic acid peaked at day 15 for both dosing groups during a 29 day treatment period. Mean  $C_{max}$  and  $AUC_{0-24h}$  values of tazarotenic acid from subjects in the 15% body surface area dosing group were more than 10 times higher than those from subjects in the face-only dosing group. The single highest  $C_{max}$  throughout the trial period was 1.91 ng/mL on day 15 in the exaggerated dosing group. In the face-only group, the mean  $\pm$  SD values of  $C_{max}$  and  $AUC_{0-24h}$  of tazarotenic acid on day 15 were 0.10  $\pm$  0.06 ng/mL and 1.54  $\pm$  1.01 ng·hr/mL, respectively, whereas in the 15% body surface area dosing group, the mean  $\pm$  SD values of  $C_{max}$  and  $AUC_{0-24h}$  of tazarotenic acid on day 15 were 1.20  $\pm$  0.41 ng/mL and 17.01  $\pm$  6.15 ng·hr/mL, respectively. The steady state pharmacokinetics of tazarotenic

acid had been reached by day 8 in the face-only and by day 15 in the 15% body surface area dosing groups.

In a Phase 3 clinical trial, TAZORAC Cream, 0.1% was applied once daily for 12 weeks to each of 48 subjects (22 females and 26 males) with facial acne vulgaris. The mean  $\pm$  SD values of plasma tazarotenic acid at weeks 4 and 8 were  $0.078 \pm 0.073$  ng/mL (N=47) and  $0.052 \pm 0.037$  ng/mL (N=42), respectively. The highest observed individual plasma tazarotenic acid concentration was 0.41 ng/mL at week 4 from a female subject. The magnitude of plasma tazarotenic acid concentrations appears to be independent of gender, age, and body weight.

## 13 NONCLINICAL TOXICOLOGY

### 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

#### *Carcinogenesis*

A long-term study of tazarotene following oral administration of 0.025, 0.050, and 0.125 mg/kg/day to rats showed no indications of increased carcinogenic risks. Based on pharmacokinetic data from a shorter term study in rats, the highest dose of 0.125 mg/kg/day was anticipated to give systemic exposure in the rat equivalent to 0.6 times that seen in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/kg/cm<sup>2</sup> over a 35% body surface area in a controlled pharmacokinetic study. This estimated systemic exposure in rats was 2 times the maximum systemic exposure in acne patients treated with tazarotene cream, 0.1% cream at 2 mg/cm<sup>2</sup> over a 15% body surface area.

A long-term topical application study of up to 0.1% of tazarotene in a gel formulation in mice terminated at 88 weeks showed that dose levels of 0.05, 0.125, 0.25, and 1 mg/kg/day (reduced to 0.5 mg/kg/day for males after 41 weeks due to severe dermal irritation) revealed no apparent carcinogenic effects when compared to vehicle control animals. Systemic exposures at the highest dose was 3.9 times that seen in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<sup>2</sup> over a 35% body surface area in a controlled pharmacokinetic study, and 13 times the maximum systemic exposure in acne patients treated with tazarotene cream, 0.1% at 2 mg/cm<sup>2</sup> over a 15% body surface area.

In evaluation of photo co-carcinogenicity, median time to onset of tumors was decreased, and the number of tumors increased in hairless mice following chronic topical dosing with intercurrent exposure to ultraviolet radiation at tazarotene concentrations of 0.001%, 0.005%, and 0.01% in a gel formulation for up to 40 weeks.

#### *Mutagenesis*

Tazarotene was found to be non-mutagenic in the Ames assay and did not produce structural chromosomal aberrations in a human lymphocyte assay. Tazarotene was non-mutagenic in the CHO/HGPRT mammalian cell forward gene mutation assay and was non-clastogenic in the *in vivo* mouse micronucleus test.

#### *Impairment of Fertility*

No impairment of fertility occurred in rats when male animals were treated for 70 days prior to mating and female animals were treated for 14 days prior to mating and continuing through gestation and lactation with topical doses of tazarotene gel up to 0.125 mg/kg/day. Based on data from another study, the systemic drug exposure in the rat would be equivalent to 0.6 times that observed in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<sup>2</sup> over a 35% body surface area in a controlled pharmacokinetic study, and 2 times the maximum systemic exposure in acne patients treated with tazarotene cream, 0.1% at 2 mg/cm<sup>2</sup> over a 15% body surface area.

No impairment of mating performance or fertility was observed in male rats treated for 70 days prior to mating with oral doses of up to 1 mg/kg/day tazarotene. That dose produced a systemic exposure that was 1.9 times that observed in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<sup>2</sup> over a 35% body surface area, and 6.3 times the maximum systemic exposure in acne patients treated with tazarotene cream, 0.1% at 2 mg/cm<sup>2</sup> over a 15% body surface area.

No impairment of mating performance or fertility was observed in female rats treated for 15 days prior to mating and continuing through gestation day 7 with oral doses up to 2 mg/kg/day of tazarotene. However, there was a significant decrease in the number of estrous stages and an increase in developmental effects at that dose [see *Use in Specific Populations (8.1)*]. That dose produced a systemic exposure that was 3.4 times that observed in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<sup>2</sup> over a 35% body surface area and 11 times the maximum systemic exposure in acne patients treated with tazarotene cream, 0.1% at 2 mg/cm<sup>2</sup> over a 15% body surface area.

Reproductive capabilities of F1 animals, including F2 survival and development, were not affected by topical administration of tazarotene gel to female F0 parental rats from gestation day 16 through lactation day 20 at the maximum tolerated dose of 0.125 mg/kg/day. Based on data from another study, the systemic drug exposure in the rat would be equivalent to 0.6 times that observed in a psoriatic patient treated with 0.1% tazarotene cream at 2 mg/cm<sup>2</sup> over a 35% body surface area, and 2 times the maximum systemic exposure in acne patients treated with tazarotene cream, 0.1% at 2 mg/cm<sup>2</sup> over a 15% body surface area.

**14 CLINICAL STUDIES**

In two 12-week vehicle-controlled clinical trials, TAZORAC Cream, 0.05% and 0.1% was significantly more effective than vehicle in reducing the severity of stable plaque psoriasis. TAZORAC Cream, 0.1% and 0.05% demonstrated superiority over vehicle cream as early as 1 week and 2 weeks, respectively, after starting treatment.

In these trials, the primary efficacy endpoint was “clinical success,” defined as the proportion of subjects with none, minimal, or mild overall lesional assessment at Week 12, and shown in Table 1. “Clinical success” was also significantly greater with TAZORAC Cream, 0.05% and 0.1% versus vehicle at most follow-up visits.

**Table 1. Subject Numbers and Percentages for Overall Lesional Assessment Scores and “Clinical Success” at Baseline (BL), End of Treatment (Week 12) and 12 Weeks After Stopping Therapy (Week 24)<sup>#</sup> in Two Controlled Clinical Trials for Psoriasis**

| Score              | TAZORAC Cream, 0.05% |              |              |                  |              |       | TAZORAC Cream, 0.1% |              |              |                  |               |       | Vehicle Cream    |              |              |                  |       |             |
|--------------------|----------------------|--------------|--------------|------------------|--------------|-------|---------------------|--------------|--------------|------------------|---------------|-------|------------------|--------------|--------------|------------------|-------|-------------|
|                    | Trial 1<br>N=218     |              |              | Trial 2<br>N=210 |              |       | Trial 1<br>N=221    |              |              | Trial 2<br>N=211 |               |       | Trial 1<br>N=229 |              |              | Trial 2<br>N=214 |       |             |
|                    | BL                   | Wk 12        | Wk 24        | BL               | Wk 12        | Wk 24 | BL                  | Wk 12        | Wk 24        | BL               | Wk 12         | Wk 24 | BL               | Wk 12        | Wk 24        | BL               | Wk 12 | Wk 24       |
| None (0)           | 0                    | 1<br>(0.5%)  | 1<br>(0.5%)  | 0                | 2<br>(1%)    |       | 0                   | 0            | 0            | 0                | 6<br>(3%)     |       | 0                | 0            | 1<br>(0.4%)  | 0                |       | 1<br>(0.5%) |
| Minimal (1)        | 0                    | 11<br>(5%)   | 12<br>(6%)   | 0                | 7<br>(3%)    |       | 0                   | 12<br>(5%)   | 14<br>(6%)   | 0                | 11<br>(5%)    |       | 0                | 7<br>(3%)    | 6<br>(3%)    | 0                |       | 1<br>(0.5%) |
| Mild (2)           | 0                    | 79<br>(36%)  | 60<br>(28%)  | 0                | 76<br>(36%)  |       | 0                   | 75<br>(34%)  | 53<br>(24%)  | 0                | 90<br>(43%)   |       | 0                | 49<br>(21%)  | 43<br>(19%)  | 0                |       | 54<br>(25%) |
| Moderate (3)       | 141<br>(65%)         | 86<br>(39%)  | 90<br>(41%)  | 100<br>(48%)     | 74<br>(35%)  |       | 122<br>(55%)        | 97<br>(44%)  | 107<br>(48%) | 96<br>(45%)      | 62<br>(29%)   |       | 139<br>(61%)     | 119<br>(52%) | 114<br>(50%) | 97<br>(45%)      |       | 99<br>(46%) |
| Severe (4)         | 69<br>(32%)          | 39<br>(18%)  | 51<br>(23%)  | 80<br>(38%)      | 36<br>(17%)  |       | 91<br>(41%)         | 36<br>(16%)  | 46<br>(21%)  | 86<br>(41%)      | 29<br>(14%)   |       | 81<br>(35%)      | 51<br>(22%)  | 61<br>(27%)  | 93<br>(44%)      |       | 47<br>(22%) |
| Very Severe (5)    | 8<br>(4%)            | 2<br>(0.9%)  | 4<br>(2%)    | 30<br>(14%)      | 15<br>(7%)   |       | 8<br>(4%)           | 1<br>(0.5%)  | 1<br>(0.5%)  | 29<br>(14%)      | 13<br>(6%)    |       | 9<br>(4%)        | 3<br>(1%)    | 4<br>(2%)    | 24<br>(11%)      |       | 12<br>(6%)  |
| “Clinical Success” | 0                    | 91<br>(42%*) | 73<br>(33%*) | 0                | 85<br>(40%*) |       | 0                   | 87<br>(39%*) | 67<br>(30%*) | 0                | 107<br>(51%*) |       | 0                | 56<br>(24%)  | 50<br>(22%)  | 0                |       | 56<br>(26%) |

0 no plaque elevation above normal skin level; may have residual non-erythematous discoloration; no psoriatic scale

1 essentially flat with possible trace elevation; may have up to moderate erythema (red coloration); no psoriatic scale

2 slight but definite elevation of plaque above normal skin level; may have up to moderate erythema (red coloration); fine scales with some lesions partially covered

3 moderate elevation with rounded or sloped edges to plaque; moderate erythema (red coloration); somewhat coarser scales with most lesions partially covered

4 marked elevation with hard, sharp edges to plaque; severe erythema (very red coloration); thick scales with virtually all lesions covered and a rough surface

5 very marked elevation with very hard, sharp edges to plaque; very severe erythema (extreme red coloration); very coarse, thick scales with all lesions covered and a very rough surface

Clinical Success defined as an overall lesional assessment score of none, minimal, or mild.

**# Trial 1 had post-treatment period observations for 12 weeks after stopping therapy, which were not part of Trial 2.**

**\* Denotes statistically significant difference for “Clinical Success” compared with vehicle.**

At the end of 12 weeks of treatment, TAZORAC Cream, 0.05% and 0.1% was consistently superior to vehicle in reducing the plaque thickness of psoriasis. Improvements in erythema and scaling were generally significantly greater with TAZORAC Cream, 0.05% and 0.1% than with vehicle. TAZORAC Cream, 0.1% was also generally more effective than TAZORAC Cream, 0.05% in reducing the severity of the individual signs of disease. However, TAZORAC Cream, 0.1% was associated with a greater degree of local irritation than TAZORAC Cream, 0.05%.

**Table 2. Mean Decreases in Plaque Elevation, Scaling and Erythema in Two Controlled Clinical Trials for Psoriasis**

| Lesion | TAZORAC Cream, 0.05%   |         |                    |         |             |         | TAZORAC Cream, 0.1%    |         |                    |         |             |         | Vehicle Cream          |         |                    |         |             |         |
|--------|------------------------|---------|--------------------|---------|-------------|---------|------------------------|---------|--------------------|---------|-------------|---------|------------------------|---------|--------------------|---------|-------------|---------|
|        | Trunk/Arm/ Leg lesions |         | Knee/Elbow lesions |         | All Treated |         | Trunk/Arm/ Leg lesions |         | Knee/Elbow lesions |         | All Treated |         | Trunk/Arm/ Leg lesions |         | Knee/Elbow lesions |         | All Treated |         |
|        | Trial 1                | Trial 2 | Trial 1            | Trial 2 | Trial 1     | Trial 2 | Trial 1                | Trial 2 | Trial 1            | Trial 2 | Trial 1     | Trial 2 | Trial 1                | Trial 2 | Trial 1            | Trial 2 | Trial 1     | Trial 2 |
|        | N=218                  | N=210   | N=218              | N=210   | N=218       | N=210   | N=221                  | N=211   | N=221              | N=211   | N=221       | N=211   | N=229                  | N=214   | N=229              | N=214   | N=229       | N=214   |



|                  |           |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |             |
|------------------|-----------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Plaque elevation | <b>B#</b> | <b>2.29</b> | <b>2.50</b> | <b>2.40</b> | <b>2.52</b> | <b>2.28</b> | <b>2.51</b> | <b>2.34</b> | <b>2.52</b> | <b>2.35</b> | <b>2.49</b> | <b>2.32</b> | <b>2.51</b> | <b>2.28</b> | <b>2.51</b> | <b>2.35</b> | <b>2.51</b> | <b>2.29</b> | <b>2.51</b> |
|                  | C-12      | -0.83*      | -0.98*      | -0.91*      | -1.04*      | -0.75*      | -0.90*      | -1.08*      | -1.25*      | -0.96*      | -1.21*      | -0.83*      | -1.08*      | -0.59       | -0.69       | -0.57       | -0.68       | -0.48       | -0.61       |
|                  | C-24      | -0.75*      |             | -0.73*      |             | -0.60*      |             | -0.87*      |             | -0.73*      |             | -0.63*      |             | -0.57       |             | -0.49       |             | -0.42       |             |
| Scaling          | <b>B#</b> | <b>2.26</b> | <b>2.45</b> | <b>2.47</b> | <b>2.60</b> | <b>2.32</b> | <b>2.47</b> | <b>2.37</b> | <b>2.45</b> | <b>2.40</b> | <b>2.57</b> | <b>2.36</b> | <b>2.53</b> | <b>2.34</b> | <b>2.46</b> | <b>2.45</b> | <b>2.61</b> | <b>2.31</b> | <b>2.53</b> |
|                  | C-12      | -0.75       | -0.90       | -0.78*      | -0.98*      | -0.67*      | -0.80       | -0.84*      | -1.06*      | -0.76*      | -1.13*      | -0.73*      | -1.03*      | -0.66       | -0.79       | -0.62       | -0.76       | -0.46       | -0.70       |
|                  | C-24      | -0.68       |             | -0.62*      |             | -0.51*      |             | -0.79*      |             | -0.61*      |             | -0.59*      |             | -0.56       |             | -0.45       |             | -0.34       |             |
| Erythema         | <b>B#</b> | <b>2.26</b> | <b>2.51</b> | <b>2.17</b> | <b>2.40</b> | <b>2.23</b> | <b>2.48</b> | <b>2.25</b> | <b>2.53</b> | <b>2.17</b> | <b>2.42</b> | <b>2.21</b> | <b>2.51</b> | <b>2.24</b> | <b>2.47</b> | <b>2.17</b> | <b>2.34</b> | <b>2.24</b> | <b>2.47</b> |
|                  | C-12      | -0.49       | -0.65*      | -0.44       | -0.66*      | -0.40       | -0.62       | -0.49       | -0.82*      | -0.57*      | -0.82*      | -0.42*      | -0.78*      | -0.42       | -0.46       | -0.38       | -0.44       | -0.37       | -0.47       |
|                  | C-24      | -0.52       |             | -0.44       |             | -0.41       |             | -0.55       |             | -0.52*      |             | -0.39*      |             | -0.43       |             | -0.34       |             | -0.33       |             |

Plaque elevation, scaling and erythema scored on a 0-4 scale with 0=none, 1=mild, 2=moderate, 3=severe and 4=very severe.

B#=Mean Baseline Severity;

C-12=Mean Change from Baseline at end of 12 weeks of therapy;

C-24=Mean Change from Baseline at week 24 (12 weeks after the end of therapy).

**\*Denotes statistically significant difference compared with vehicle.**

Acne:

In two large vehicle-controlled trials, subjects age 12 years and over with facial acne vulgaris of a severity suitable for monotherapy with a topical agent were enrolled. After face cleansing in the evening, TAZORAC Cream, 0.1% was applied once daily to the entire face as a thin layer. TAZORAC Cream, 0.1% was significantly more effective than vehicle in the treatment of facial acne vulgaris. Efficacy results after 12 weeks of treatment are shown in Table 3:

**Table 3. Efficacy Results after Twelve Weeks of Treatment in Two Controlled Clinical Trials for Acne**

|  | TAZORAC Cream, 0.1% |                  | Vehicle Cream    |                  |
|--|---------------------|------------------|------------------|------------------|
|  | Trial 1<br>N=218    | Trial 2<br>N=206 | Trial 1<br>N=218 | Trial 2<br>N=205 |
| Median Percent Reduction in                                  |                     |                  |                  |                  |
| • Noninflammatory lesions                                    | 46%*                | 41%*             | 27%              | 21%              |
| • Inflammatory lesions                                       | 41%*                | 44%*             | 27%              | 25%              |
| • Total lesions  | 44%*                | 42%*             | 24%              | 21%              |
| Percent of Subjects with No Acne or Minimal Acne             | 18%*                | 20%*             | 11%              | 6%               |
| Percent of Subjects with No Acne, Minimal Acne, or Mild Acne | 55%*                | 53%*             | 36%              | 36%              |

**\*Denotes statistically significant difference compared with vehicle.**

## 16 HOW SUPPLIED/STORAGE AND HANDLING

TAZORAC Cream is a white cream available in concentrations of 0.05% and 0.1%. It is supplied in a collapsible aluminum tube with a tamper-evident aluminum membrane over the opening and a white polypropylene screw cap, in 30 g and 60 g sizes.

| TAZORAC Cream, 0.05% |                  | TAZORAC Cream, 0.1% |                  |
|----------------------|------------------|---------------------|------------------|
| 30 g                 | NDC 0023-9155-30 |                     | NDC 0023-9156-30 |
| 60 g                 | NDC 0023-9155-60 |                     | NDC 0023-9156-60 |

Storage: Store at 20°C to 25°C (68°F to 77°F). Excursions permitted from -5°C to 30°C (23°F to 86°F).

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

### Embryofetal Toxicity

Inform females of reproductive potential of the potential risk to a fetus. Advise these patients to use effective contraception during treatment with TAZORAC Cream. Advise patients to inform their

healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.1) and Use in Specific Populations (8.1, 8.3)].

### Photosensitivity and Risk of Sunburn

Advise patients to avoid excessive sun exposure and to use of sunscreens and protective measures (hat, visor). Advise patients to avoid using TAZORAC if also taking other medicines may increase sensitivity to sunlight.

### Important Administration Instructions

Advise the patient of the following:

1. For the patient with psoriasis, apply TAZORAC Cream only to psoriasis skin lesions, avoiding uninvolved skin.
2. If undue irritation (redness, peeling, or discomfort) occurs, reduce frequency of application or temporarily interrupt treatment. Treatment may be resumed once irritation subsides [see Dosage and Administration (2.1)].
3. Moisturizers may be used as frequently as desired.
4. Patients with psoriasis may use a cream or lotion to soften or moisten skin at least 1 hour before applying TAZORAC Cream.
5. Avoid contact with the eyes. If TAZORAC Cream gets in or near eyes, rinse thoroughly with water. Seek medical attention if eye irritation continues.
6. TAZORAC Cream is for topical use only. Do not apply to eyes, mouth, or other mucous membrane. Not for ophthalmic, oral, or intravaginal use.
7. Wash hands thoroughly after applying TAZORAC Cream.

© 2017 Allergan. All rights reserved.

All trademarks are the property of their respective owners.

Irvine, CA 92612

Made in the U.S.A.



72709US11

#### PATIENT INFORMATION

#### TAZORAC® (TAZ-or-ac)

(tazarotene)

Cream, 0.05% and 0.1%

**Important information:** TAZORAC Cream is for use on skin only. Do not use TAZORAC Cream in your eyes, mouth, or vagina.

#### What is the most important information I should know about TAZORAC Cream?

**TAZORAC Cream may cause birth defects if used during pregnancy.**

- **Females must not be pregnant when they start using TAZORAC Cream or become pregnant during treatment with TAZORAC Cream.**
- For females who are able to get pregnant:
  - Your doctor will order a pregnancy test for you within 2 weeks before you begin treatment with TAZORAC Cream to be sure that you are not pregnant. Your doctor will decide when to do the test.
  - Begin treatment with TAZORAC Cream during a normal menstrual period.
  - Use an effective form of birth control during treatment with TAZORAC Cream. Talk with your doctor about birth control options that may be used to prevent pregnancy during treatment with TAZORAC Cream.
  - **Stop using TAZORAC Cream and tell your doctor right away if you become pregnant while using TAZORAC Cream.**

#### What is TAZORAC Cream?

- TAZORAC Cream 0.05% and 0.1% is a prescription medicine used on the skin (topical) to treat people with plaque psoriasis.
- TAZORAC Cream 0.1% is also used on the skin to treat people with acne vulgaris.
- It is not known if TAZORAC Cream is safe and effective for:
  - the treatment of plaque psoriasis in children under 18 years of age

- the treatment of acne vulgaris in children under 12 years of age

#### **Who should not use TAZORAC Cream?**

##### **Do not use TAZORAC Cream if you:**

- are pregnant or plan to become pregnant. See “What is the most important information I should know about TAZORAC Cream?” at the beginning of this leaflet.
- are allergic to tazarotene or any of the ingredients in TAZORAC Cream. See the end of this leaflet for a complete list of ingredients in TAZORAC Cream.

#### **What should I tell my doctor before using TAZORAC Cream?**

##### **Before you use TAZORAC Cream, tell your doctor about all of your medical conditions, including if you:**

- have eczema or any other skin problems
- are breastfeeding or plan to breastfeed. It is not known if TAZORAC Cream passes into your breast milk. Talk to your doctor about using TAZORAC Cream while breastfeeding.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

##### **Certain medicines, vitamins, or supplements may make your skin more sensitive to sunlight.**

Also, tell your doctor about any cosmetics you use, including moisturizers, creams, lotions, or products that can dry out your skin.

#### **How should I use TAZORAC Cream?**

- Use TAZORAC Cream exactly as your doctor tells you to use it.
- Apply TAZORAC Cream 1 time each day, in the evening.
- **Do not** get TAZORAC Cream in your eyes, on your eyelids, or in your mouth. If TAZORAC Cream gets in or near your eyes, rinse them well with water. Call your doctor or get medical help if you have eye irritation that does not go away.
- Wash your hands after applying TAZORAC Cream.

#### **Follow these instructions for applying TAZORAC Cream:**

- **If you have psoriasis:**
  - If you shower or bathe before applying TAZORAC Cream, your skin should be dry before applying the cream.
  - You may use a cream or lotion to soften or moisten your skin at least 1 hour before you apply TAZORAC Cream.
  - Apply a thin layer of TAZORAC Cream to cover only the psoriasis lesions.
- **If you have acne:**
  - Gently wash and dry your face before applying TAZORAC Cream.
  - Apply a thin layer of TAZORAC Cream to cover only the acne lesions.
- If you swallow TAZORAC Cream, call your doctor or go to the nearest hospital emergency room right away.

#### **What should I avoid while using TAZORAC Cream?**

- Avoid sunlight, including sunlamps, during treatment with TAZORAC Cream. TAZORAC Cream can make you more sensitive to the sun, and the light from sunlamps and tanning beds. You could get a severe sunburn. Use sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight.
- Talk to your doctor if you get a sunburn during treatment with TAZORAC Cream. If you get a sunburn, do not use TAZORAC Cream until your sunburn is healed.
- Avoid using cosmetics or topical medicines that may make your skin more sensitive to sunlight or make your skin dry.
- Avoid using TAZORAC Cream on unaffected skin or skin with eczema because it may cause severe irritation.

#### **What are the possible side effects of TAZORAC Cream?**

##### **TAZORAC Cream may cause serious side effects, including:**

- **Skin irritation and allergic reactions (hypersensitivity).** TAZORAC Cream may cause increased skin irritation and hives. Tell your doctor if you develop hives, or itching, burning, redness, or peeling of your skin during treatment with TAZORAC Cream. If you develop hives or skin irritation, your doctor may tell you to stop using TAZORAC Cream until your skin heals, tell you to use TAZORAC Cream less often, or change your TAZORAC Cream dose. Also, wind or cold weather may be more irritating to your skin while you are using TAZORAC Cream.
- **Sensitivity to sunlight and risk of sunburn.** See “What should I avoid while using TAZORAC Cream?”

**The most common side effects of TAZORAC Cream in people with psoriasis include** itching, redness and burning.

**The most common side effects of TAZORAC Cream in people with acne include** peeling, dry skin, redness and burning.

These are not all the possible side effects of TAZORAC Cream. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

**How should I store TAZORAC Cream?**

- Store TAZORAC Cream at room temperature between 68°F to 77°F (20°C to 25°C).
- Keep TAZORAC Cream and all medicines out of the reach of children.

**General information about the safe and effective use of TAZORAC Cream.**

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use TAZORAC Cream for a condition for which it was not prescribed. Do not give TAZORAC Cream to other people, even if they have the same symptoms you have. It may harm them. You can ask your doctor or pharmacist for information about TAZORAC Cream that is written for health professionals.

**What are the ingredients in TAZORAC Cream?**

**Active ingredient:** tazarotene

**Inactive ingredients:** benzyl alcohol 1%, carbomer 1342, carbomer homopolymer type B, edetate disodium, medium chain triglycerides, mineral oil, purified water, sodium hydroxide, sodium thiosulfate, and sorbitan monooleate

Manufactured by: Allergan Sales, LLC.,  
Waco, Texas



© 2017 Allergan. All rights reserved.

All trademarks are the property of their respective owners.

Irvine, CA , 92612

Made in the U.S.A.

For more information call 1-800-678-1605 or go to [www.tazorac.com](http://www.tazorac.com).

This Patient Information has been approved by the U.S. Food and Drug Administration

Revised: July/2017

72709US11

NDC 0023-9155-60      **Rx only**

**60 grams**

**TAZORAC®  
(TAZAROTENE)  
cream, 0.05%**

**For Topical Use Only  
Not for Ophthalmic Use**

**ALLERGAN®**



NDC 0023-9156-60 Rx only

60 grams

**TAZORAC®**  
(TAZAROTENE)  
cream, 0.1%

For Topical Use Only  
Not for Ophthalmic Use

ALLERGAN®



**TAZORAC**

tazarotene cream

| Product Information  |                         |                    |               |
|--|-------------------------|--------------------|---------------|
| Product Type   | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:0023-9155 |
| Route of Administration  | CUTANEOUS               |                    |               |
| Active Ingredient/Active Moiety  |                         |                    |               |
| Ingredient Name  | Basis of Strength       | Strength           |               |
| tazarotene (UNII: 81BDR9Y8PS) (tazarotene - UNII:81BDR9Y8PS)                       | tazarotene              | 0.5 mg in 1 g      |               |
| Inactive Ingredients   |                         |                    |               |
| Ingredient Name  | Strength                |                    |               |
| Benzyl alcohol (UNII: LKG8494WBH)  |                         |                    |               |
| CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: HHT01ZNK31) |                         |                    |               |
| carbomer 1342 (UNII: 809Y72KV36)   |                         |                    |               |
| edetate disodium (UNII: 7FLD91C86K)  |                         |                    |               |
| GLYCERYL CAPRYLOCAPRATE (UNII: U72Q218C85)   |                         |                    |               |
| mineral oil (UNII: T5L8T28FGP)   |                         |                    |               |
| water (UNII: 059QF0KO0R)   |                         |                    |               |
| sodium thiosulfate (UNII: HX1032V43M)  |                         |                    |               |
| sorbitan monooleate (UNII: 06XEA2VD56)   |                         |                    |               |
| sodium hydroxide (UNII: 55X04QC32I)  |                         |                    |               |

| Packaging |                   |  |                      |                    |
|-----------|-------------------|--|----------------------|--------------------|
| #         | Item Code         | Package Description                                | Marketing Start Date | Marketing End Date |
| 1         | NDC:0023-9 155-30 | 1 in 1 CARTON                                      | 11/15/2000           |                    |
| 1         |                   | 30 g in 1 TUBE; Type 0: Not a Combination Product  |                      |                    |
| 2         | NDC:0023-9 155-60 | 1 in 1 CARTON                                      | 11/15/2000           |                    |
| 2         |                   | 60 g in 1 TUBE; Type 0: Not a Combination Product  |                      |                    |
| 3         | NDC:0023-9 155-15 | 1 in 1 CARTON                                      | 11/15/2000           |                    |
| 3         |                   | 3.5 g in 1 TUBE; Type 0: Not a Combination Product |                      |                    |

| Marketing Information |  |                      |                    |
|-----------------------|--|----------------------|--------------------|
| Marketing Category    | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA                   | NDA021184                                | 11/15/2000           |                    |

## TAZORAC

tazarotene cream

| Product Information     |                         |                    |                |
|-------------------------|-------------------------|--------------------|----------------|
| Product Type            | HUMAN PRESCRIPTION DRUG | Item Code (Source) | NDC:0023-9 156 |
| Route of Administration | CUTANEOUS               |                    |                |

| Active Ingredient/Active Moiety                                    |                   |             |
|--|-------------------|-------------|
| Ingredient Name  | Basis of Strength | Strength    |
| tazarotene (UNII: 8 1BDR9 Y8 PS) (tazarotene - UNII:8 1BDR9 Y8 PS) | tazarotene        | 1 mg in 1 g |

| Inactive Ingredients  |          |
|---|----------|
| Ingredient Name   | Strength |
| Benzyl alcohol (UNII: LKG8494WBH)   |          |
| CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED) (UNII: HHT0 1ZNK31) |          |
| carbomer 1342 (UNII: 809 Y72KV36)   |          |
| edetate disodium (UNII: 7FLD9 1C86K)  |          |
| GLYCERYL CAPRYLOCAPRATE (UNII: U72Q2I8C85)  |          |
| mineral oil (UNII: T5L8T28FGP)  |          |
| water (UNII: 059 QF0K00R)   |          |
| sodium thiosulfate (UNII: HX1032V43M)   |          |
| sorbitan monooleate (UNII: 06 XEA2VD56)   |          |
| sodium hydroxide (UNII: 55X04QC32I)   |          |

| Packaging |                   |  |                      |                    |
|-----------|-------------------|--|----------------------|--------------------|
| #         | Item Code         | Package Description                                | Marketing Start Date | Marketing End Date |
| 1         | NDC:0023-9 156-30 | 1 in 1 CARTON                                      | 11/13/2000           |                    |
| 1         |                   | 30 g in 1 TUBE; Type 0: Not a Combination Product  |                      |                    |
| 2         | NDC:0023-9 156-60 | 1 in 1 CARTON                                      | 11/13/2000           |                    |
| 2         |                   | 60 g in 1 TUBE; Type 0: Not a Combination Product  |                      |                    |
| 3         | NDC:0023-9 156-15 | 1 in 1 CARTON                                      | 11/13/2000           |                    |
| 3         |                   | 3.5 g in 1 TUBE; Type 0: Not a Combination Product |                      |                    |

| Marketing Information |  |                      |                    |
|-----------------------|--|----------------------|--------------------|
| Marketing Category    | Application Number or Monograph Citation | Marketing Start Date | Marketing End Date |
| NDA                   | NDA021184                                | 11/13/2000           |                    |

Labeler - Allergan, Inc. (144796497)

